Vaxart, Inc. (VXRT), Wednesday announced pre-clinical data showcasing the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination for the treatment of human papillomavirus or HPV-related cervical dysplasia.
According to the study published in Vaccines journal, the vaccine has the ability to stimulate specific T cell immune responses, reduce tumor size, and increase survival rates in mice with HPV-related tumors.
Sean Tucker, Vaxart's Founder and Chief Scientific Officer, said, "... these initial findings suggest that our mucosal vaccine platform could open the door to a non-invasive approach designed to prevent the progression to cervical cancer."
Currently, Vaxart's stock is trading at $0.8643, down 2.7 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.